NCT00405444

Brief Summary

The purpose of this study is to determine whether intranasal fentanyl is better than placebo at decreasing pain in children 4-8 years of age during urinary catheterization for a VCUG study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at below P25 for phase_3 pain

Timeline
Completed

Started Nov 2006

Typical duration for phase_3 pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

November 28, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 30, 2006

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
Last Updated

December 13, 2010

Status Verified

December 1, 2010

Enrollment Period

1.8 years

First QC Date

November 28, 2006

Last Update Submit

December 10, 2010

Conditions

Keywords

PediatricsPainVoiding CystourethrogramCatheterizationFentanyl

Outcome Measures

Primary Outcomes (1)

  • Change in pain before and after catheterization for the VCUG.

    Will be measured up until 30 mins after the VCUG procedure.

Secondary Outcomes (3)

  • Heart rate, respiratory rate and oxygen saturation just prior to and after the administration of fentanyl.

    Every 5 minutes until 30 minutes after the VCUG procedure.

  • Nausea, vomiting, itching, nasal pain/irritation or any other side effects.

    Will be measured up until 30 mins after the VCUG procedure.

  • Length of stay in diagnostic suite

    Time frame determined by outcome

Study Arms (2)

1

EXPERIMENTAL
Drug: Fentanyl

2

PLACEBO COMPARATOR
Drug: Sterile water

Interventions

The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.

1

The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.

2

Eligibility Criteria

Age4 Years - 8 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Age 4-8 years
  • Scheduled VCUG at Sick Kids
  • Understand the consent and assent form in English

You may not qualify if:

  • Previous adverse events to fentanyl or any opioid
  • History of a chronic respiratory or cardiac illness
  • Children with developmental delay
  • Children with bilateral nasal congestion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada

Location

Related Publications (1)

  • Chung S, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Pediatr Radiol. 2010 Jul;40(7):1236-40. doi: 10.1007/s00247-009-1521-1. Epub 2010 Feb 24.

    PMID: 20180109BACKGROUND

MeSH Terms

Conditions

Pain

Interventions

Fentanyl

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Seen Chung, MD

    The Hospital for Sick Children, Toronto Canada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 28, 2006

First Posted

November 30, 2006

Study Start

November 1, 2006

Primary Completion

September 1, 2008

Study Completion

September 1, 2008

Last Updated

December 13, 2010

Record last verified: 2010-12

Locations